NCT05838729View on ClinicalTrials.gov

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Head Neck CancerIntratumoral Injection
Interventions
DRUG

RiMO-301

"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."

Trial Locations (1)

60612

RECRUITING

University of Illinois at Chicago, Chicago

Sponsors
All Listed Sponsors
collaborator

University of Illinois at Chicago

OTHER

lead

Coordination Pharmaceuticals, Inc.

INDUSTRY

NCT05838729 - Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer | Biotech Hunter | Biotech Hunter